Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
This activity has been designed to meet the educational needs of Oncologists and Hematology Oncologists, as well as all healthcare providers involved in managing patients with Metastatic Melanoma (MM).
After participating in this educational activity, participants should be better able to:
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-038-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service at custserv@napb.net
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
ALLISON BETOF WARNER, MD, PHD, faculty for this educational event, is a contracted researcher for Iovance Biotherapeutics, Bristol Myers Squibb, and Trisalis Life Sciences; and receives consulting fees from Bristol Myers Squibb, BluePath Solutions, Immatics, Instil Bio, Iovance Biotherapeutics, Lyell Immunopharma, Novartis, Merck and, Pfizer.
Hussein Tawbi, MD, PhD, faculty for this educational event, is a contracted researcher for Bristol Myers-Squibb, Novartis, Merck, Genentech, GlaxoSmithKline, EMD Serono, Eisai, Dragonfly Therapeutics and, RAPT Therapeutics; and receives consulting fees from Bristol Myers-Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm,l Iovanc, Eisa, Jazz Pharmaceuticals and, Medicenna.
The following reviewers, managers, planners, and relevant staff reported they do not have any financial relationships with any ineligible companies:
Brian P. McDonough, MD, FAAP has nothing to disclose.
Megan Reimann, PharmD, BCOP has nothing to disclose.
Leticia Samaras has nothing to disclose.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Global Learning Collaborative (GLC) and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
This activity is supported by an independent educational grant from Bristol Myers Squibb.
During the period 04/26/2024 through 04/26/2025, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
Release Date:
Expiration Date:
